v3 Template
C

Clene Inc.

Biopharmaceutical Las Vegas, NV ~440 employees
Founded
--
Employees (Est.)
~440
22 leaders known
Total Funding
$177.7M
Funding Rounds
7
Last Funding
2026-01-09

About Clene Inc.

Clene Inc. is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases by restoring and protecting neuronal health and function through nanotherapeutics that target cellular energy impairments.

Products & Services

CNM-Au8:A nanotherapeutic product aimed at addressing neurodegenerative diseases.
Nanotherapeutic Platform:A platform for creating clean-surfaced, catalytically-active nanocrystals for therapeutic use, targeting high unmet medical needs in neurodegenerative diseases.

Specialties

Nanomedicine Neurodegenerative Disease Treatment Nanotherapeutics

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering 		A: 28000000
MR: -
FA: approximately $28 million
FAN: 28000000 		D: 2026-01-09
FD: 2026-01-09 		3 investors
2 RT: Debt
T: -
FT: Debt 		A: 10000000
MR: -
FA: $10.0 million
FAN: 10000000 		D: 2024-12-19
FD: 2024-12-19 		-
3 RT: Registered Direct Offering and Concurrent Private Placements
T: -
FT: Registered Direct Offering and Concurrent Private Placements 		A: 7300000
MR: -
FA: 7.3 million
FAN: 7300000 		D: 2024-10-01
FD: 2024-10-01 		5 investors
4 RT: Registered Direct Offering and Private Placements
T: -
FT: Registered Direct Offering and Private Placements 		A: 7300000
MR: -
FA: 7.3 million
FAN: 7300000 		D: 2024-09-30
FD: 2024-09-30 		3 investors
5 RT: Grant
T: -
FT: Grant 		A: 45100000
MR: -
FA: $45.1 million
FAN: 45100000 		D: 2023-10-05
FD: 2023-10-05 		1 investors
6 RT: Underwritten Public Offering
T: -
FT: Underwritten Public Offering 		A: 40000000
MR: -
FA: $40 million
FAN: 40000000 		D: 2023-06-21
FD: 2023-06-21 		5 investors
7 RT: Public Offering
T: -
FT: Public Offering 		A: 40000000
MR: -
FA: $40 million
FAN: 40000000 		D: 2023-06-16
FD: 2023-06-16 		3 investors
Registered Direct Offering Latest
2026-01-09
$28.0M
3 investors (Pro only)
Debt 2024-12-19
$10.0M
Registered Direct Offering and Concurrent Private Placements 2024-10-01
$7.3M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

D

David J. Matlin

Chairman

R

Rob Etherington

President & Chief Executive Officer

A

Arjun "JJ" Desai, MD

Board Member

J

Jonathon T. Gay

Board Member

S

Shalom Jacobovitz

Board Member

M

Matthew Kiernan AM, Ph.D., DSc

Board Member

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

Clene Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
clene.com
Industries
Biopharmaceutical
Company Size
~440 employees (est.)
Locations
Las Vegas, NV
Salt Lake City, Utah

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro